# Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

> **NCT02126020** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **James Chodosh, MD, MPH**

## Conditions studied

- Stevens-Johnson Syndrome
- Toxic Epidermal Necrolysis (Lyell) Syndrome
- Mucous Membrane Pemphigoid

## Interventions

- **DRUG:** topical infliximab

## Key facts

- **NCT ID:** NCT02126020
- **Lead sponsor:** James Chodosh, MD, MPH
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-11
- **Primary completion:** 2017-04-03
- **Final completion:** 2017-04-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients met eligibility criteria. The study has been closed.
- **Last updated:** 2017-04-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02126020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02126020, "Topical Infliximab in Autoimmune Eyes With Keratoprosthesis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02126020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*